BioAge Labs, Inc. (NASDAQ:BIOA) Receives $43.50 Average Target Price from Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $43.50.

BIOA has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Needham & Company LLC initiated coverage on shares of BioAge Labs in a research note on Friday, March 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Citigroup boosted their price objective on shares of BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Roth Mkm initiated coverage on shares of BioAge Labs in a research note on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th.

BioAge Labs Stock Up 5.0%

Shares of NASDAQ:BIOA opened at $23.76 on Tuesday. BioAge Labs has a 12-month low of $4.07 and a 12-month high of $24.93. The business has a 50 day moving average of $18.05 and a 200-day moving average of $17.87. The stock has a market cap of $1.06 billion, a PE ratio of -9.90 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The company had revenue of $2.77 million during the quarter. Equities research analysts expect that BioAge Labs will post -2.68 earnings per share for the current year.

Hedge Funds Weigh In On BioAge Labs

A number of institutional investors and hedge funds have recently made changes to their positions in BIOA. GSA Capital Partners LLP bought a new position in BioAge Labs in the 3rd quarter valued at about $181,000. R Squared Ltd bought a new position in BioAge Labs in the 3rd quarter valued at about $154,000. Nano Cap New Millennium Growth Fund L P bought a new position in BioAge Labs in the 4th quarter valued at about $1,058,000. Stempoint Capital LP bought a new position in BioAge Labs in the 1st quarter valued at about $5,923,000. Finally, Octagon Capital Advisors LP lifted its position in BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after acquiring an additional 150,000 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.